Tolperisone
M03B - Muscle relaxants, centrally acting agents
ATC M03BX04
Small molecule
Natural product
JFDA label: Myomax 150mg F.C Tab
Indications
Off-label
- Arthralgia
- Low Back Pain
- Muscle Spasticity
- Myalgia
Chemistry & Properties
| Formula | C16H23NO |
|---|
| Molecular weight | 245.37 g/mol |
|---|
| IUPAC name | 2-methyl-1-(4-methylphenyl)-3-piperidin-1-ylpropan-1-one |
|---|
| CAS | 728-88-1 |
|---|
| PubChem CID | 5511 |
|---|
| InChIKey | FSKFPVLPFLJRQB-UHFFFAOYSA-N |
|---|
| logP | 3.3 (XLogP 3.4) |
|---|
| Polar surface area | 20.31 Ų |
|---|
| H-bond acceptors / donors | 2 / 0 |
|---|
| Drug-likeness (QED) | 0.76 |
|---|
| Lipinski violations | 0 |
|---|
SMILES
Cc1ccc(C(=O)C(C)CN2CCCCC2)cc1Biology & Pharmacokinetics
Pharmacokinetics predicted
| Bioavailability | 70.0% |
|---|
| Half-life | 0.753 h |
|---|
| Volume of distribution | 3.921 L/kg |
|---|
| Protein binding | 77.7% |
|---|
| BBB penetrant | Yes |
|---|
Enzyme interactions
| Enzyme | Role | Detail |
|---|
| CYP1A2 | Substrate |
— |
| CYP2B6 | Inhibitor |
— |
| CYP2C19 | Substrate |
— |
| CYP2D6 | Inhibitor |
— |
| CYP2D6 | Substrate |
— |
| CYP3A4 | Substrate |
— |
Transporters
BCRP (Inhibitor)BSEP (Inhibitor)MRP1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)P-gp (Inhibitor)P-gp (Substrate)
Registered Products (6)
| Brand | Form / strength | Pack | Agent | Citizen (JOD) |
|---|
| Mayocure Tablet
|
Tablet 150 mg |
30 tab |
SANA PHARMACEUTICAL INDUSTRY/JORDAN |
5.840 |
| Myomax 150mg F.C Tab
|
Film-Coated Tablet 150 mg |
30 tab |
UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN |
6.110 |
| Stiffano
|
Tablet 150 mg |
30 tab |
Jordan Sweden Medical & Sterilization Co. |
6.110 |
| Mydocalm
|
Tablet 150 mg |
30 tab pack varies |
ORIENT DRUG STORE CO |
6.490 |
| Mydocalm
|
Tablet 150 mg |
100 tab pack varies |
ORIENT DRUG STORE CO |
20.340 |
| Mydocalm
|
Tablet 150 mg |
500 tab pack varies |
ORIENT DRUG STORE CO |
94.110 |